Hematology is one of the areas in which active interactions and mutual stimulations between clinical medicine and basic science have been producing remarkable progress. We are trying to obtain deeper insights into mechanisms of and develop effective treatments for various hematological diseases, with a motto, “from bedside to bench, from bench to bedside”.
Research and EducationWe perform our research, focusing on “cure” of hematological malignancies and infectious diseases, by bidirectional approaches, that is, from bedside to bench, and from bench to bedside. Our research extends over both basic science and clinical medicine in hematology, immunology and virology, and covers diverse fields as follows: 1) basic and clinical research on the pathophysiology and the treatment of hematological malignancies including leukemia, MDS, lymphoma, myeloma and ATL, 2) basic and clinical research on oncogenic mechanisms mediated by APOBEC3-induced genome mutagenesis and the impaired DNA repair systems in cancer cells, 3) application of iPS cell technology to basic and clinical research on hematological disorders and regenerative medicine of the blood, 4) basic and clinical research on the pathophysiology of infectious diseases including HIV, and host defense against them, 5) basic and clinical research on dendritic cells and tumor immunotherapy, and 6) basic and clinical research on hematopoietic stem cell transplantation and cellular immunotherapy. By these researches, we aim to elucidate the pathophysiology of hematological malignancies and infectious diseases, thereby develop novel diagnostics and therapeutic strategies and apply them to clinical practice.
(Picture) Department members （April, 2018）
- Inano S, Sato K, Katsuki Y, Kobayashi W, Tanaka H, Nakajima K, Nakada S, Miyoshi H, Knies K, Takaori-Kondo A, Schindler D, Ishiai M, Kurumizaka H, Takata M. RFWD3-Mediated Ubiquitination Promotes Timely Removal of Both RPA and RAD51 from DNA Damage Sites to Facilitate Homologous Recombination. Mol Cell. 66(5):622-634, 2017.
- Takiuchi Y, Kobayashi M, Tada K, Iwai F, Sakurada M, Hirabayashi S, Nagata K, Shirakawa K, Shindo K, Yasunaga JI, Murakawa Y, Rajapakse V, Pommier Y, Matsuoka M, Takaori-Kondo A. HTLV-1 bZIP factor suppresses TDP1 expression through inhibition of NRF-1 in adult T-cell leukemia. Sci Rep. 7(1): 12849, 2017.
- Ishiyama K, Kitawaki T, Sugimoto N, Sozu T, Anzai N, Okada M, Nohgawa M, Hatanaka K, Arima N, Ishikawa T, Tabata S, Onaka T, Oka S, Nakabo Y, Amakawa R, Matsui M, Moriguchi T, Takaori-Kondo A, Kadowaki N. Principal component analysis uncovers cytomegalovirus-associated NK cell activation in Ph+ leukemia patients treated with dasatinib. Leukemia 2017;31(1):203-12.
- Fujii S, Miura Y, Fujishiro A, Shindo T, Shimazu Y, Hirai H, Tahara H, Takaori-Kondo A, Ichinohe T, Maekawa T. GVHD amelioration by human bone marrow mesenchymal stromal/stem cell-derived extracellular vesicles is associated with peripheral preservation of naïve T cell populations. Stem Cells. 36(3): 434-45, 2018.
- Maeda T, Nagano S, Ichise H, Kataoka K, Yamada D, Ogawa S, Koseki H, Kitawaki T, Kadowaki N, Takaori-Kondo A, Masuda K, Kawamoto H. Regeneration of CD8αβ T cells from T cell-derived iPSC imparts potent tumor antigen-specific cytotoxicity. Cancer Res. 76(23):6839-50, 2016.
Hematology and OncologyProfessor: Akifumi Takaori-Kondo
Associate Professor: Kouhei Yamashita
Senior Lecturer: Tadakazu Kondo
Senior Lecturer: Momoko Nishikori
Assistant Professor: Keisuke Shindo
Assistant Professor: Masakatsu Hishizawa
Assistant Professor: Toshio Kitawaki
Assistant Professor: Takero Shindo
Assistant Professor: Kotaro Shirakawa
Assistant Professor: Akihiro Imura
Assistant Professor: Junya Kanda
Assistant Professor: Takashi Miyoshi